How estrogen fuels breast cancer

Future Oncology

Volumn 6, Issue 9, 2010, Pages 1369-1371

  Rana, Ajay ^a   Rangasamy, Velusamy ^a   Mishra, Rajakishore ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

breast cancer; cytotoxic drug; estrogen; estrogen receptor

Indexed keywords

AROMATASE INHIBITOR; CERAMIDE; ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; MITOGEN ACTIVATED PROTEIN KINASE 10; MIXED LINEAGE KINASE 3; PACLITAXEL; PROTEIN KINASE B; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; DRUG EFFICACY; DRUG TARGETING; EDITORIAL; HUMAN; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL;

BREAST NEOPLASMS; ESTROGENS; FEMALE; HUMANS; MAP KINASE KINASE KINASES;

EID: 77957946628     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.112     Document Type: Editorial

References (15)

1. Irvin WJ Jr, Carey LA: What is triplenegative breast cancer? Eur. J. Cancer 44, 2799-2805 (2008).
2. Edwards DP: Regulation of signal transduction pathways by estrogen and progesterone. Annu. Rev. Physiol. 67, 335-376 (2005).
3. Colditz GA: Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J. Natl Cancer Inst. 90, 814-823 (1998).
4. Hankinson SE, Colditz GA, Willett WC: Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res. 6, 213-218 (2004).
5. Jensen EV, Jordan VC: The estrogen receptor: a model for molecular medicine. Clin. Cancer Res. 9, 1980-1989 (2003).
6. Iwase H: Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer. Breast Cancer 15, 278-290 (2008).
7. Gompel A, Somai S, Chaouat M et al.: Hormonal regulation of apoptosis in breast cells and tissues. Steroids 65, 593-598 (2000).
8. Gallo KA and Johnson GL: Signalling: mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat. Rev. Mol. Cell Biol. 3, 663-672 (2002).
9. Wang LH, Besirli CG, Johnson EM Jr: Mixed-lineage kinases: a target for the prevention of neurodegeneration. Annu. Rev. Pharmacol. Toxicol. 44, 451-474 (2004).
10. Rana A, Gallo K, Godowski P et al.: The mixed lineage kinase SPRK phosphorylates and activates the stress-activated protein kinase activator, SEK-1. J. Biol. Chem. 271, 19025-19028 (1996).
11. Barthwal MK, Sathyanarayana P, Kundu CN et al.: Negative regulation of mixed lineage kinase 3 by protein kinase B/AKT leads to cell survival. J. Biol. Chem. 278, 3897-3902 (2003).
12. Riggins RB, Bouton AH, Liu MC, Clarke R: Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer. Vitam. Horm. 71, 201-237 (2005).
13. Xu Z, Maroney AC, Dobrzanski P, Kukekov NV, Greene LA: The MLK family mediates c-Jun N-terminal kinase activation in neuronal apoptosis. Mol. Cell Biol. 21, 4713-4724 (2001). (Pubitemid 32588252)
14. Rangasamy V, Mishra R, Mehrotra S et al.: Estrogen suppresses MLK3-mediated apoptosis sensitivity in ER+ breast cancer cells. Cancer Res. 70, 1731-1740 (2010).
15. Sathyanarayana P, Barthwal MK, Kundu CN et al.: Activation of the Drosophila MLK by ceramide reveals TNF-a and ceramide as agonists of mammalian MLK3. Mol. Cell. 10, 1527-1533 (2002).